The FDA approved Iyuzeh for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, according to a press release from Thea Pharma.
Iyuzeh (latanoprost ophthalmic solution 0.005%) is the first preservative-free formulation of latanoprost available in the U.S.
In randomized, controlled clinical trials in patients with a mean baseline IOP of 19 mm Hg to 24 mm Hg, Iyuzeh lowered IOP by 3 mm Hg to 8 mm Hg while Xalatan (latanoprost ophthalmic solution 0.005%, Viatris), which is preserved with benzalkonium chloride, lowered IOP by 4 (Read more...)